Damora Therapeutics, Inc. (DMRA) - Net Assets
Based on the latest financial reports, Damora Therapeutics, Inc. (DMRA) has net assets worth $240.38 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($260.53 Million) and total liabilities ($20.15 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Damora Therapeutics, Inc. liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $240.38 Million |
| % of Total Assets | 92.27% |
| Annual Growth Rate | 34.2% |
| 5-Year Change | 105.06% |
| 10-Year Change | N/A |
| Growth Volatility | 548.16 |
Damora Therapeutics, Inc. - Net Assets Trend (2018–2025)
This chart illustrates how Damora Therapeutics, Inc.'s net assets have evolved over time, based on quarterly financial data. Also explore total assets of Damora Therapeutics, Inc. for the complete picture of this company's asset base.
Annual Net Assets for Damora Therapeutics, Inc. (2018–2025)
The table below shows the annual net assets of Damora Therapeutics, Inc. from 2018 to 2025. For live valuation and market cap data, see Damora Therapeutics, Inc. market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $240.38 Million | +1561.12% |
| 2024-12-31 | $14.47 Million | -55.24% |
| 2023-12-31 | $32.33 Million | -47.64% |
| 2022-12-31 | $61.75 Million | -47.32% |
| 2021-12-31 | $117.22 Million | -29.17% |
| 2020-12-31 | $165.49 Million | +241.42% |
| 2019-12-31 | $48.47 Million | +58.09% |
| 2018-12-31 | $30.66 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Damora Therapeutics, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 45434600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Comprehensive Income | $802.00K | 0.33% |
| Other Components | $726.94 Million | 302.41% |
| Total Equity | $240.38 Million | 100.00% |
Damora Therapeutics, Inc. Competitors by Market Cap
The table below lists competitors of Damora Therapeutics, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sanyang Motor Co Ltd
TW:2206
|
$1.46 Billion |
|
Gosuncn Technology Group Co Ltd Class A
SHE:300098
|
$1.46 Billion |
|
Fushun Special Steel Co Ltd
SHG:600399
|
$1.46 Billion |
|
Doosan Pref Shs
KO:000155
|
$1.46 Billion |
|
Prodea Real Estate Investment Co.
AT:PRODEA
|
$1.46 Billion |
|
WEBTOON Entertainment Inc. Common stock
NASDAQ:WBTN
|
$1.46 Billion |
|
Lufax Holding Ltd
NYSE:LU
|
$1.46 Billion |
|
Tansun Technology Co Ltd
SHE:300872
|
$1.46 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Damora Therapeutics, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 14,471,000 to 240,380,000, a change of 225,909,000 (1561.1%).
- Net loss of 209,839,000 reduced equity.
- New share issuances of 266,811,000 increased equity.
- Other comprehensive income increased equity by 705,000.
- Other factors increased equity by 168,232,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-209.84 Million | -87.29% |
| Share Issuances | $266.81 Million | +111.0% |
| Other Comprehensive Income | $705.00K | +0.29% |
| Other Changes | $168.23 Million | +69.99% |
| Total Change | $- | 1561.12% |
Book Value vs Market Value Analysis
This analysis compares Damora Therapeutics, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.14x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.82x to 0.14x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $30.14 | $24.86 | x |
| 2019-12-31 | $47.64 | $24.86 | x |
| 2020-12-31 | $163.77 | $24.86 | x |
| 2021-12-31 | $116.01 | $24.86 | x |
| 2022-12-31 | $60.76 | $24.86 | x |
| 2023-12-31 | $30.42 | $24.86 | x |
| 2024-12-31 | $12.51 | $24.86 | x |
| 2025-12-31 | $181.14 | $24.86 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Damora Therapeutics, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -87.29%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.08x
- Recent ROE (-87.29%) is below the historical average (-80.77%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -51.76% | 0.00% | 0.00x | 1.14x | $-18.93 Million |
| 2019 | -75.32% | 0.00% | 0.00x | 1.17x | $-41.35 Million |
| 2020 | -21.05% | 0.00% | 0.00x | 1.04x | $-51.39 Million |
| 2021 | -44.15% | 0.00% | 0.00x | 1.04x | $-63.47 Million |
| 2022 | -99.79% | 0.00% | 0.00x | 1.19x | $-67.80 Million |
| 2023 | -118.61% | 0.00% | 0.00x | 1.18x | $-41.58 Million |
| 2024 | -148.15% | 0.00% | 0.00x | 1.18x | $-22.89 Million |
| 2025 | -87.29% | 0.00% | 0.00x | 1.08x | $-233.88 Million |
Industry Comparison
This section compares Damora Therapeutics, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $161,374,297
- Average return on equity (ROE) among peers: -386.97%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $240.38 Million | -51.76% | 0.08x | $1.46 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $98.20 Million |
| Abcellera Biologics Inc (ABCL) | $1.14 Billion | -12.83% | 0.19x | $1.57 Billion |
| Abeona Therapeutics Inc (ABEO) | $681.00K | -3192.95% | 12.43x | $313.99 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $179.85 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $189.45 Million | -60.80% | 0.14x | $793.56 Million |
| Arbutus Biopharma Corp (ABUS) | $26.88 Million | -30.41% | 0.07x | $854.72 Million |
| ABVC Biopharma Inc (ABVC) | $-1.46 Million | 0.00% | 0.00x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.66 Million | -45.66% | 0.56x | $9.73 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $84.98 Million | -24.53% | 0.28x | $3.65 Billion |
About Damora Therapeutics, Inc.
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to u… Read more